CAR-T for Leukemia in China: Treatment Coordination for International Patients
While the FDA has approved six CAR-T therapies with list prices from $373,000 to $475,000 per infusion, commercial CAR-T products in China are priced between $70,000 and $120,000 — a gap that reshapes treatment geography for patients with relapsed or refractory leukemia. That price difference is not a discount for inferior care. Chinese hospitals now run more active CAR-T clinical trials than any country except the United States, with over 600 registered studies. The question is no longer whether CAR-T for leukemia is available in China for foreigners. It is how to arrange it without wasting months or money.
Our team at China Medical Services coordinates this process daily. We do not sell CAR-T. We connect patients with the hospitals that actually run these programs, handle the documentation, and translate between two very different medical systems. Here is what that process looks like in practice.
How This Actually Works, Step by Step
The sequence is not complicated, but each step has hidden waiting periods. Knowing them upfront prevents frustration.
First, you send us the patient’s existing records: diagnosis, pathology report, bone marrow biopsy results, cytogenetics, prior treatment lines, and current blood counts. These must be in English or Chinese. If they are in another language, translation takes an extra 3–5 business days. We forward the translated records to one or more hospitals with active CAR-T programs for leukemia. A hematologist reviews them — typically within 5–10 working days. You receive a written assessment: whether the patient is a candidate, which CAR-T product or trial fits, and the estimated treatment cost.
If you decide to proceed, we coordinate a video consultation with the treating team. The doctor explains the protocol, the hospitalization period, the risks, and what monitoring happens afterward. You ask questions directly. After that, the hospital issues a treatment plan and cost estimate. You sign a consent form. Then we move to logistics: S2 visa documents, travel dates, hospital admission scheduling, and — critically — a bilingual medical companion who stays with the patient through the entire inpatient period.
Is CAR-T for Leukemia Available in China for Foreigners?
Plan for 3 to 4 months. Record review takes 2–4 weeks. Video consultation and treatment planning take another 1–2 weeks. Visa processing takes 2–4 weeks. Pre-treatment evaluation in China takes about a week. Then lymphodepletion and infusion. If the patient’s disease is progressing rapidly, the timeline can compress — but not by much.
Most Western insurers do not cover treatment in China unless you have a specific international or expatriate policy that includes China. Some policies cover second opinions or consultations. Treatment itself is usually self-pay. You pay the hospital upfront, then submit claims to your insurer for whatever portion they reimburse. Check your policy before committing.
CAR-T fails in a significant minority of leukemia patients — roughly 30–50% depending on disease type and prior treatment lines. If the disease relapses after CAR-T, options include a second CAR-T with a different target, bispecific antibodies, or allogeneic transplant. The treating hospital will discuss next steps. We coordinate whatever path you choose.
Yes, for at least 4 weeks. The hospital will not discharge you before the acute toxicity window closes. After discharge, some patients stay locally for another 1–2 months for monitoring. Others return home with a written follow-up protocol. The decision depends on your home country’s hematology capacity and your personal circumstances.
Your Next Step
CAR-T for leukemia in China is a real option for international patients who cannot access or afford treatment at home. The path exists. It is navigable. But it requires honest medical review before any commitment, and it requires coordination on the ground once you arrive. Our team handles the record translation, hospital matching, consultation scheduling, visa documentation, and bilingual companionship. We do not promise outcomes. We do not guarantee admission. We make the process clear, fast, and less frightening.
Start with your medical records. Send them to us for a free initial review, and we will tell you honestly whether CAR-T in China is a realistic path for your case — and which hospitals are worth contacting. Request a free consultation and we will respond within one business day.
Frequently Asked Questions
Yes. The hospitals used for international patients are JCI-accredited and follow the same international safety standards as top hospitals in the US and Europe. Surgical teams perform high volumes of procedures — often more than their Western counterparts — which studies show leads to better outcomes.
Costs vary by procedure and hospital, but international patients typically save 40-80% compared to US prices — even when factoring in travel and accommodation. A consultation with our team will give you an exact, all-inclusive quote with no hidden fees.
Send us your existing medical reports to get started. We handle everything from hospital selection and appointment scheduling to visa assistance and post-operative recovery planning. Your medical records are reviewed by the specialist before you even book a flight.
For more medical information and treatment options in China, visit chinamedservices.com (China Medical Services).
